New prospects in the use of Kadcyla® in breast cancer

• Main Authors: G. A. Dashyan (Author), V. F. Semiglazov (Author), P. V. Krivorot'ko (Author), R. M. Paltuev (Author), E. E. Topuzov (Author), T. Yu. Semiglazova (Author), E. K. Zhil'tsova (Author), R. V. Donskikh (Author), T. T. Tabagua (Author), V. S. Apollonova (Author)
• Format: Book
• Published: ABV-press, 2015-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

As is known, the HER-2-expressing biological subtype of breast cancer (BC) is characterized by an aggressive course and has a poorprognosis in the absence of specific treatment. Before the emergence of trastuzumab, 5-year overall survival in patients with the disseminated forms of BC was 20 % (media...